SE0102184D0 - New subject-matter - Google Patents

New subject-matter

Info

Publication number
SE0102184D0
SE0102184D0 SE0102184A SE0102184A SE0102184D0 SE 0102184 D0 SE0102184 D0 SE 0102184D0 SE 0102184 A SE0102184 A SE 0102184A SE 0102184 A SE0102184 A SE 0102184A SE 0102184 D0 SE0102184 D0 SE 0102184D0
Authority
SE
Sweden
Prior art keywords
subject matter
new subject
mesotocin
oxytocin
tri
Prior art date
Application number
SE0102184A
Other languages
English (en)
Swedish (sv)
Inventor
Kerstin Uvnaes-Moberg
Thomas Lundeberg
Maria Petersson
Original Assignee
Uvnaes Moberg Kerstin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uvnaes Moberg Kerstin filed Critical Uvnaes Moberg Kerstin
Priority to SE0102184A priority Critical patent/SE0102184D0/xx
Publication of SE0102184D0 publication Critical patent/SE0102184D0/xx
Priority to EP02739051A priority patent/EP1409518B1/de
Priority to DE60224280T priority patent/DE60224280D1/de
Priority to US10/481,623 priority patent/US7714105B2/en
Priority to AT02739051T priority patent/ATE382054T1/de
Priority to PCT/SE2002/001207 priority patent/WO2002102832A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE0102184A 2001-06-19 2001-06-19 New subject-matter SE0102184D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0102184A SE0102184D0 (sv) 2001-06-19 2001-06-19 New subject-matter
EP02739051A EP1409518B1 (de) 2001-06-19 2002-06-19 Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
DE60224280T DE60224280D1 (de) 2001-06-19 2002-06-19 Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
US10/481,623 US7714105B2 (en) 2001-06-19 2002-06-19 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis
AT02739051T ATE382054T1 (de) 2001-06-19 2002-06-19 Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
PCT/SE2002/001207 WO2002102832A1 (en) 2001-06-19 2002-06-19 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102184A SE0102184D0 (sv) 2001-06-19 2001-06-19 New subject-matter

Publications (1)

Publication Number Publication Date
SE0102184D0 true SE0102184D0 (sv) 2001-06-19

Family

ID=20284539

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102184A SE0102184D0 (sv) 2001-06-19 2001-06-19 New subject-matter

Country Status (6)

Country Link
US (1) US7714105B2 (de)
EP (1) EP1409518B1 (de)
AT (1) ATE382054T1 (de)
DE (1) DE60224280D1 (de)
SE (1) SE0102184D0 (de)
WO (1) WO2002102832A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101045438B1 (ko) * 2004-03-31 2011-06-30 톳쿄기쥬츠 가이하츠 가부시키가이샤 상피계 세포증식 촉진제
WO2011027060A2 (fr) 2009-09-04 2011-03-10 Centre National De La Recherche Scientifique - Crns - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
SE536091C2 (sv) 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
MX2018012351A (es) 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
JP6527996B2 (ja) * 2017-09-12 2019-06-12 株式会社 金冠堂 Ｆｇｆ活性に影響を与えるジペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) * 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
EP0146113A3 (de) 1983-12-15 1987-08-19 Dieter Aderhold Wirkstoff und therapeutisches Mittel zur Behandlung von Fehlfunktionen des Diencephalon, von Nervenerkrankungen und Erkrankungen der Haut
US5767083A (en) * 1994-05-04 1998-06-16 Innapharma, Inc. Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
SE9803271D0 (sv) 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for well-being

Also Published As

Publication number Publication date
US7714105B2 (en) 2010-05-11
DE60224280D1 (de) 2008-02-07
EP1409518B1 (de) 2007-12-26
ATE382054T1 (de) 2008-01-15
WO2002102832A1 (en) 2002-12-27
US20040259805A1 (en) 2004-12-23
EP1409518A1 (de) 2004-04-21

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CY1108547T1 (el) Αναλογα σωματοστατινης
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
TW200505875A (en) Novel compounds
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
NO992102D0 (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
WO2006081826A3 (en) Survivin peptide vaccine
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
EP1545599A4 (de) Immunogene zusammensetzungen und ihre diagnostische und therapeutische verwendung
EP1423137A4 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
PL374080A1 (en) Processes for the preparation of fibrinogen
PL1622939T3 (pl) Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
DE50113345D1 (de) Arginin-mimetika als faktor xa-inhibitoren
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
DE60233071D1 (de) Pharmazeutische zusammensetzungen auf basis von azetidinderivaten
PT1290160E (pt) Polipeptideos pellino humanos
DK1476467T3 (da) IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf
SE0200657D0 (sv) Novel Formulation
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
BRPI0408446A (pt) tablete de limpeza
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias
SE0101220D0 (sv) New use